A course of intravenous infusions that bind and flush out metals, including toxic lead and the body's own calcium, in the hope of softening diseased arteries. Removing heavy metals is its best-established action; plaque dissolving is largely theoretical. Trial evidence is conflicting, and after the latest large trial the case for vascular rejuvenation has weakened. (Full Review)

Protocol

Standard trial regimen

40 weekly IV infusions

~500 mL solution with 3 g disodium EDTA, ascorbate, B vitamins, magnesium, procaine, heparin; infused over at least 3 hours; up to 10 maintenance infusions follow.

Dosing form

Intravenous, repeated infusions

Short plasma half-life (~20–60 min) and very poor oral absorption mean the therapeutic form is intravenous; oral EDTA products are not supported by the trial evidence.

Supervision requirement

Clinician-administered only

Cannot be self-administered; requires repeated supervised intravenous infusions with renal and electrolyte monitoring.

Time to effect

Blood-metal reduction

Across the 40 infusions

Reductions accrue progressively across the infusions rather than after any single session.

Vascular benefit

Months to years

The studied benefit, where seen, emerged over months to years of a multi-month infusion course.

Perceptible effect

None perceptible

There is no quick or perceptible effect from any single infusion.

Benefits

High: Reduction of body lead and cadmium burden

Medium: Reduction in composite cardiovascular events after heart attack; greater apparent benefit in people with diabetes

Low: Improvement in peripheral arterial function

Speculative: Slowing of arterial calcification or plaque regression; generalized "anti-aging" vascular benefit in healthy adults

Contraindications

Significant kidney impairment (serum creatinine >2.0 mg/dL or eGFR <30 mL/min/1.73 m²)

Decompensated heart failure (NYHA Class IV)

Pregnancy and breastfeeding

Uncorrected low blood calcium

Key Interactions

Insulin and oral glucose-lowering drugs (e.g., glipizide, glimepiride)

Digoxin

Anticoagulants (e.g., warfarin, apixaban)

Mineral-containing antacids, calcium or magnesium supplements

Aspirin and other OTC blood thinners

Iron, zinc, calcium, and magnesium supplements

Blood-pressure-lowering agents (antihypertensives, high-dose nitrates, beetroot/nitrate, high-dose omega-3)

High-dose intravenous vitamin C

Risk & Side Effects

High: Hypocalcemia

Medium: Kidney injury; depletion of essential minerals

Low: Infusion-site and systemic reactions; hypoglycemia

Speculative: Indirect harm from delaying proven therapy; long-term cumulative effects of repeated lifelong infusions

Monitoring

Marker	Target	Why
Serum creatinine / eGFR	Creatinine <1.0 mg/dL; eGFR >90 mL/min/1.73 m²	Confirms kidneys can clear EDTA-metal complexes
Serum calcium	9.4–9.8 mg/dL	EDTA binds calcium; low levels raise arrhythmia/seizure risk
Serum magnesium	2.0–2.5 mg/dL	Depleted by chelation; low levels destabilize heart rhythm
Serum potassium	4.0–4.5 mmol/L	Electrolyte shifts during infusion can affect rhythm
Serum zinc	90–120 µg/dL	EDTA removes zinc; depletion affects immunity and glucose handling
Blood lead	<3.5 µg/dL (lower is better)	Tracks the metal-removal rationale and confirms drug effect
Fasting glucose / HbA1c	Glucose 70–90 mg/dL; HbA1c <5.4%	Relevant to the diabetic population and hypoglycemia risk

Cadence: Electrolytes and renal markers at baseline, periodically through the 40-infusion induction phase (commonly every several infusions), and again before maintenance infusions, then every 6–12 months if treatment continues.

Qualitative Assessment

Energy levels and exertional tolerance
Walking distance and leg symptoms (for peripheral arterial disease)
Frequency or severity of chest discomfort (angina)
Infusion tolerability (site reactions, post-infusion fatigue, lightheadedness)
Cognitive clarity and general well-being

EDTA Chelation for Vascular Rejuvenation

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment